CD4CARNK-92 cells

N/A

Report date: 2025/01/26 19:36:36

Base Information

Drug NameCD4CARNK-92 cells

Drug Alias Nameanti-CD4 CAR NK-cell therapy (iCell Gene Therapeutics)

ClassificationCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > Natural killer cell therapy > Chimeric antigen receptor NK cell therapyBiologics > Protein drugs > Recombinant protein > Fusion protein

Mechanisms of ActionT-cell surface antigen CD4 modulators

TargetsT-cell surface antigen CD4

Therapy Area/IndicationsLymphoma, T-Cell

Global Approved IndicationsN/A

Approved Indications in ChinaN/A

Original Approved Country/TerritoryN/A

Original Approved DateN/A

Country/TerritoryUnited States

CombinationsNo

Global Highest StatusPreclinical

Highest Status in ChinaN/A

Originator CompaniesiCell Gene Therapeutics LLC

China Registration ClassN/A

Develop Information

Active CompaniesiCell Gene Therapeutics LLC

Inactive CompaniesN/A

Active IndicationsLymphoma, T-Cell

Inactive IndicationsN/A

Other Information

ATC CodeN/A